Chief Scientific Officer
Philippe holds a PhD in Molecular Biology from the Université Libre de Bruxelles (ULB) obtained in 1993 and a Master in Management de l’Innovation from HEC Saint Louis (Brussels, Belgium) obtained in 1995. In 1995-1996 Philippe did a post-doctoral research at the University of Edinburgh (UK). During this research he discovered using mouse model the function of the alpha-fetoprotein the major embryonic plasma protein in mammalian development. During his academic research career he was involved has an inventor in the development of a portfolio of genetic selection patented technologies. One of these technologies belonging to ULB was licensed to Life technologies and is on the market since 1995 it is today a standard in DNA assembly method: Gateway technology, TOPO cloning. Other technologies were licensed to Sanofi-Pasteur, GSK and Merck to improve biopharmaceutical production. Since 2001-to 2012 Philippe was the Founder and CEO of Delphi Genetics today part of CATALENT. Since 2013 Philippe is the founder and Chief Scientific Officer of Syngulon a startup focusing on genetic innovations to improve the biocontrol of microbial population using bacteriocins (antimicrobial peptides). Philippe has established several partnerships for the company with academics and industries.